Christopher G. Cann, MD

Christopher Cann, MD
This physician is not currently rated. Why?

Why is this doctor not rated?


To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles. Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive evaluation and ratings from patients.

More about patient ratings

Assistant Professor, Department of Hematology/Oncology

Gastrointestinal Cancer Program


  • Gastrointestinal Medical Oncology

Areas of Expertise

Appendix Cancer, Pancreatic Cancer, Liver, Gall Bladder & Bile Duct Cancer, Neuroendocrine Tumors, Esophageal Cancer, Colorectal Cancer, Stomach (Gastric) Cancer

Treatment Focus

Gastrointestinal Cancers; Young Adult Oncology 

Treatment Philosophy

It is an honor to join the oncology team at Fox Chase Cancer Center.  During my time as a medical student rotating at Fox Chase and through the experience of my own family, I have witnessed personally the unparalleled compassionate care and clinical excellence Fox Chase provides to patients. After completing my Internal Medicine and Hematology/Oncology training at Vanderbilt University Medical Center, I hoped to return home to the Philadelphia area and have been fortunate enough to continue my career at the institution where my medical training began. 

I chose to pursue a career in the treatment and research of gastrointestinal cancers due to the patients that I cared for during my residency and fellowship. Many of the patients I treated were young adults when they developed their disease, and they allowed me to see first-hand the unique psychosocial and emotional struggles young adults with malignancies face, motivating me to pursue a career serving them. My goal is to provide the most novel, cutting-edge treatment to each of my patients in parallel with optimal supportive care to mitigate symptom burden and maximize quality of life. Additionally, I hope to play an integral role in development of clinical trials to expand treatment options for all those with GI malignancies. 

Clinical Locations

  • Fox Chase Cancer Center
    333 Cottman Avenue
    Philadelphia, PA 19111
    Phone: 888-369-2427

Educational Background

Undergraduate Training: University of Maryland, College Park, College Park, Maryland, Bachelor of Science in Biological Sciences, Physiology and Neurobiology Specialization, August 2008 – May 2012

Graduate Education: Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, Doctor of Medicine, August 2013 – May 2017

Vanderbilt University School of Medicine, Nashville, Tennessee, Clinical Trials I Course, Master of Science in Clinical Investigation, October 2021 – November 2021

Residency Training:  Vanderbilt University Medical Center, Department of Medicine: Internal Medicine, Nashville, Tennessee, July 2017 – June 2020

Fellowship: Vanderbilt University Medical Center, Department of Medicine: Hematology/Oncology, Nashville, Tennessee, July 2020 – June 2023


  • American Board of Internal Medicine - Internal Medicine
  • American Board of Internal Medicine - Hematology
  • American Board of Internal Medicine - Medical Oncology


  • Alpha Omega Alpha Honor Medical Society 2016 – present
  • Gold Humanism Honor Society 2016 – present
  • American College of Physicians 2019 – present
  • American Medical Association 2019 – present
  • Tennessee Oncology Practice Society 2019 - present
  • American Society of Clinical Oncology 2020 – present
  • American Society of Hematology 2020 - present

Honors & Awards

Undergraduate: University of Maryland, College Park

  • Earth Life and Time Scholars Program
  • College Park Scholar Citation: 2008 – 2010
  • Primannum Honor Society
  • Phi Eta Sigma National Honor Society: 2009 - 2012
  • Alpha Lamda Delta National Honor Society: 2009 – 2012

Graduate Education: Lewis Katz School of Medicine at Temple University

  • St. Luke’s Scholarship: 2013-2017
  • Stabler Endowed Medical Scholarship 2015
  • Gold Humanism Honor Society 2016
  • Alpha Omega Alpha Honor Medical Society 2016

Fellowship: Vanderbilt University Medical Center

  • Chosen attendee for the 2021 FDA/ASCO Fellows Day Workshop
  • Education Award: Targeted Therapies of Lung Cancer Meeting 2022
  • Conquer Cancer Merit Award: ASCO Annual Meeting 2022
  • Great Debates & Updates in GI Malignancies Scholarship 2023 

Research Interests

  • Gastrointestinal cancers
  • Young adult cancer
  • Clinical trial development
  • Palliative and supportive care

Selected Publications

Cann, C. G., Tillman, B. F., Davis, E. J., & Johnson, D. B. (2019). Empiric Therapy with BRAF and MEK Inhibitors in Metastatic Melanoma. The Oncologist, 24(11), 1495. PMID: 31213499. 

Cann, C., Kopparapu, P., Yan, Y., Muterspaugh, A., Chen, H., Zhao, Z., ... & Iams, W. (2020). Prolonged time to clearance of circulating-tumor DNA from patients with limited-stage small-cell lung cancer is associated with inferior progression-free and overall survival. Clinical Cancer Research (Vol. 26, No. 11, pp. 79-79). American Association for Cancer Research Special Conference on Advances in Liquid Biopsies.  

Cann, C., & Ciombor, K. K. (2022). Systemic therapy for gastric cancer: Perioperative strategies and beyond. Journal of Surgical Oncology, 125(7), 1151-1160. PMID: 35230696.

Cann, C. G., Shen, C., LaPelusa, M. B., Agarwal, R., Cardin, D. B., & Eng, C. (2022). Supportive care (SC) utilization for patients with locally advanced pancreatic cancer: Review of the National Cancer Data Base (2004-2018). Journal of Clinical Oncology, 40(16_suppl), 4154-4154.

Cann, C. G., LaPelusa, M., Cimino, S., Grieb, B., Ciombor, K. K., Agarwal, R., ... & Eng, C. (2023). Updated analysis: Alternative biweekly dosing schedule of trifluridine-tipiracil (TAS-102) reduces rates of myelosuppression while maintaining therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC). Journal of Clinical Oncology, 41(4_suppl), 95-95. 

Cann, C. G., Lapelusa, M. B., Cimino, S. K., & Eng, C. (2023). Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements. Frontiers in Oncology, 13, 1176950. PMID: 37409250

Additional Publications

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient comments

Loading ...